EGFR and neoplasm: Sorafenib hinders the inhibition of tyrosine kinase receptors such as VEGFR-2, VEGFR-3, PDGFR-β, EGFR, c-Kit, and Flt3, which ultimately impedes the proliferation of tumor cells and angiogenesis [20], [25].